CN112292376A - 四元内酰胺类化合物及其药学用途 - Google Patents

四元内酰胺类化合物及其药学用途 Download PDF

Info

Publication number
CN112292376A
CN112292376A CN201980024128.2A CN201980024128A CN112292376A CN 112292376 A CN112292376 A CN 112292376A CN 201980024128 A CN201980024128 A CN 201980024128A CN 112292376 A CN112292376 A CN 112292376A
Authority
CN
China
Prior art keywords
compound
reaction
added
alkyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980024128.2A
Other languages
English (en)
Inventor
余尚海
冯焱
李世强
王小林
胡治隆
丁雅雯
戴飞红
贺潜
王朝东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Meiyue Biotech Development Co Ltd
Original Assignee
Shanghai Meiyue Biotech Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meiyue Biotech Development Co Ltd filed Critical Shanghai Meiyue Biotech Development Co Ltd
Publication of CN112292376A publication Critical patent/CN112292376A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

一种四元内酰胺类化合物及其制备方法和药学用途，特别是在用于制备治疗和/或预防血栓形成或血栓栓塞病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980024128.2A 2018-03-30 2019-03-29 四元内酰胺类化合物及其药学用途 Pending CN112292376A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810276765 2018-03-30
CN2018102767656 2018-03-30
PCT/CN2019/080549 WO2019185046A1 (zh) 2018-03-30 2019-03-29 四元内酰胺类化合物及其药学用途

Publications (1)

Publication Number Publication Date
CN112292376A true CN112292376A (zh) 2021-01-29

Family

ID=68059491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024128.2A Pending CN112292376A (zh) 2018-03-30 2019-03-29 四元内酰胺类化合物及其药学用途

Country Status (4)

Country Link
US (1) US11345679B2 (zh)
EP (1) EP3778588A4 (zh)
CN (1) CN112292376A (zh)
WO (1) WO2019185046A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116546984A (zh) * 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
CA3216083A1 (en) * 2021-05-06 2022-11-10 Jesper Langgaard KRISTENSEN Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufactur
TW202346278A (zh) * 2022-03-28 2023-12-01 大陸商四川海思科製藥有限公司 2-氨基吡啶衍生物製備方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1307560A (zh) * 1998-06-25 2001-08-08 布里斯托尔-迈尔斯斯奎布公司 脒基和胍基β－丙内酰胺类胰蛋白酶抑制剂
US6335324B1 (en) * 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
US20040147502A1 (en) * 2002-12-17 2004-07-29 Bisacchi Gregory S. Beta lactam compounds and their use as inhibitors of tryptase
WO2006108039A2 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
CN106029064A (zh) * 2014-02-07 2016-10-12 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180855A1 (en) * 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1307560A (zh) * 1998-06-25 2001-08-08 布里斯托尔-迈尔斯斯奎布公司 脒基和胍基β－丙内酰胺类胰蛋白酶抑制剂
US6335324B1 (en) * 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
US20040147502A1 (en) * 2002-12-17 2004-07-29 Bisacchi Gregory S. Beta lactam compounds and their use as inhibitors of tryptase
WO2006108039A2 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
CN106029064A (zh) * 2014-02-07 2016-10-12 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物

Also Published As

Publication number Publication date
US20210032219A1 (en) 2021-02-04
US11345679B2 (en) 2022-05-31
EP3778588A4 (en) 2021-04-28
WO2019185046A1 (zh) 2019-10-03
EP3778588A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
TWI717367B (zh) 經取代之側氧基吡啶衍生物
TWI736566B (zh) Ｔｌｒ７/８拮抗劑及其用途
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
EP3466955B1 (en) Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer
TWI633089B (zh) 經取代的酮基吡啶衍生物
CN102822165B (zh) 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法
CN104903320B (zh) 含氮杂环化合物或其盐
CN107106559A (zh) 自分泌运动因子的取代的螺环抑制剂
EP3095786A1 (en) Condensed 5-oxazolidinone derivative
CN109121414A (zh) 苯并吡唑化合物和其类似物
CN112292376A (zh) 四元内酰胺类化合物及其药学用途
TW201605790A (zh) 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
CN113286794A (zh) Kras突变蛋白抑制剂
CN103459382B (zh) 用于抑制pask的杂环化合物
EP3197880B1 (de) Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
WO2017037051A1 (de) Substituierte oxopyridin-derivate
WO2015044163A1 (de) Substituierte phenylalanin-derivate
CN114591212A (zh) 人类血浆激肽释放酶抑制剂
CN114230512A (zh) 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
CN106928252B (zh) 一种抑制rock的化合物及其制备方法与应用
CN103781791A (zh) 具有噁唑并[4,5-c]吡啶环的羧酸衍生物
WO2018188660A1 (zh) 一种brd4抑制剂及其制备和应用
WO2022194237A1 (zh) 喹啉衍生物及其在制备自身免疫药物上的应用
WO2021139595A1 (zh) RORγt抑制剂及其制备方法和用途
CN112010774A (zh) FXIa凝血因子抑制剂、其药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination